Recce Ltd has released a press release.
R327 Phase I Clinical Trial Registered on ANZCTR
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Recce Receives Further Innovation Connections Grant
- Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
- Anti-Viral Patent Granted in China
- Outstanding Efficacy Against Flesh-Eating Bacteria
- Multiple Patients Dosed in Topical Phase I/II Clinical Trial
Later from Recce Pharmaceuticals
- Trading halt
- Suspension from Official Quotation
- Court Orders Granted
- Reinstatement to Official Quotation
- Ethics Approval to Start Phase 1 Intravenous Clinical Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals